Matinas BioPharma Holdings, Inc. (NYSE:MTNB) traded at $0.72 at last check on Monday, Sep 14, making an upward move of 3.82% on its previous day’s price.

Looking at the stock we see that its previous close was $0.69 and the beta (5Y monthly) reads 2.8 with the day’s price range being $0.6933 – 0.7462. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, MTNB has a high of $2.49 and a low of $0.49. The company’s stock has gained about -15.11% over that past 30 days.

Matinas has a market cap of $137.73 Million and is expected to release its quarterly earnings report on August 10, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the MTNB stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.03, with the EPS growth for the year raised at -$0.12 for 2020 and -$0.17 for next year. These figures represent -0.08% and at 0.42% growth in EPS for the two years respectively.

On the other hand, looking at the outlook for the MTNB stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 6 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Matinas BioPharma Holdings, Inc. (MTNB) stock as a Hold, while 6 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the MTNB stock currently stands at 0, and the current price level is -7.57% off its SMA20 and -10% from its 50-day simple moving average. The RSI (14) is pointing at 42.15 while the volatility over the past week is 6.51% and drops to 5.72% over the past one month. The beta value is 2.8, while the average true range (ATR) is currently pointing at 0.05. The average price target for the stock over the next 12 months is $3.38, with the estimates having a low of $1.8 and a high of $5. These price ends are 150% and +594.44% off the current price level respectively, although investors could be excited at the prospect of a +351.39% if the MTNB share price touches on the median price of $3.25.

Let’s briefly compare Matinas (MTNB) stock to its peers. We find that today’s price change of +3.82% and +7.56% over the past 12 months for MTNB competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 1.43% in the latest trading session and is +32.92% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has climbed 0.16% today, and is +5.7% up over the past year, while Catalent Inc (CTLT) is also up 3.82% yet its price remains in the green at 7.56% over the same period. Zoetis has a P/E ratio of 47.58 compared to Matinas 0 and Takeda’s 22.64. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 1.27% and 1.18%, respectively, in early deals.

Coming back to Matinas BioPharma Holdings, Inc. (NYSE:MTNB), we note that the average 3-month trading volume was 2.67 Million, while that of the preceding 10-day period stands at 2Million. Current shares outstanding are 198.87 Million.

According to data from Thomson Reuters, insiders hold 8.55% of the company’s shares while institutions hold 20.78%. The data shows that short shares as of August 30, 2020, stood at 16.21 Million at a short ratio of 5.12. This represents a 8.15% Short interest in Shares outstanding on August 30, 2020. Shares short rose in August from the previous month at 16.16 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -68.29% down in year-to-date price movement.